The Scripps Research Institute (TSRI) and Janssen Pharmaceuticals are collaborating on infectious disease research, with an initial project focusing on influenza, the organizations today announced.
Under the terms of this five-year agreement, Janssen is entitled to certain license rights, and will contribute research assistance through its Crucell Vaccine Institute. This collaboration builds on previous research on the influenza virus conducted jointly by TSRI and Janssen. Financial terms of the collaboration were not disclosed.
“We’re delighted to partner with Janssen in this work that could have a significant impact on human health,” Michael Marletta, TSRI president and CEO, said in a statement. “The new agreement leverages the institute’s significant strengths in structural biology to move forward new therapies and vaccines.”